Peptovitae series will initially launch in Asia addressing a broad range of skin concerns
BASF has unveiled Peptovitae, a series of four patented peptides developed through an exclusive relationship with Korea-based biomimetic peptide R&D company Caregen.
Initially launching in Asia, the line will be made available in other regions throughout 2022.
The Peptovitae series will address a wider range of concerns than traditionally associated with the use of peptides, said BASF.
Peptovitae Matrix will combat signs of ageing, while Peptovitae Bright has been developed to enhance the brightness of skin.
To soothe skin prone to dryness and itching there is Peptovitae Derma. Finally, Peptovitae Clear aims to calm and moisturise the complexion.
A double-layered, liposome-based encapsulation system claims to let finished products optimally deliver the benefits of these new peptides.
“BASF has adapted these peptides to ensure they meet cosmetic industry standards, thereby making these products available to our customers and consumers,” said Viju Jose, Vice President, Personal Care Solutions, Care Chemicals, BASF Asia Pacific.
“Increasingly, consumers are looking for safe and effective skin care-regime-based solutions with high efficacy as an alternative to procedure-based treatments to address their personal skin needs,” added Eunice Jeong, Head of Regional Market Development, Personal Care Solutions, Care Chemicals, BASF Asia Pacific.
“The strong growth of dermocosmetics in China and the doubling of the share of dermocosmetics in the global beauty market over the last 15 years are evidence of the robust growth in products containing peptides and the shift by consumers towards biomimetic skin care regimes.”